학술논문
Use of molidustat, a hypoxia‐inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease‐associated anemia in cats
Document Type
article
Source
Journal of Veterinary Internal Medicine, Vol 38, Iss 1, Pp 197-204 (2024)
Subject
Language
English
ISSN
1939-1676
0891-6640
0891-6640
Abstract
Abstract Background Erythropoietic effects of molidustat, a hypoxia‐inducible factor prolyl hydroxylase (HIF‐PH) inhibitor, were previously demonstrated in healthy cats. Objective To evaluate the safety and erythropoietic effects of daily PO administration of molidustat in anemic cats with chronic kidney disease (CKD). Animals Twenty‐one client‐owned CKD cats (4‐17 years old) with anemia. Methods Multicenter field study; randomized, masked, and placebo‐controlled. Cats were treated PO once daily for 28 days with suspensions of control product (CP; n = 6) or 5 mg/kg of molidustat (n = 15). Hematocrit (HCT) was evaluated at weekly intervals. Individual cat treatment success was defined as a ≥4% point increase in HCT compared to baseline. Results Control group mean HCT remained low throughout the study (20.1%‐23.4%). Mean HCT of molidustat‐treated cats increased weekly, and a significant increase compared to baseline (23.6%) was first observed on Day 21 (27.3%; P